# Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.

> **NCT04679571** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 100 (estimated)

## Conditions studied

- Decompensated Cirrhosis

## Interventions

- **BIOLOGICAL:** Albumin
- **DRUG:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT04679571
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-30
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679571, "Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04679571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*